Gobi Partners GBA is part of the Pan-Asian venture capital platform Gobi Partners. Gobi GBA is the sole general partner (GP) of the Alibaba Hong Kong Entrepreneurs Fund (AEF) as well as the AEF Greater Bay Area Fund (AEF GBA Fund) and has formed strategic partnerships with other renowned financial institutions such as HSBC and Hang Seng Bank.
Gobi GBA has invested in over 70 start-ups across the Greater Bay Area and has fostered the growth of 7 unicorns including Airwallex, Amber, Animoca Brands, GoGoX, Prenetics, and more.
GenEditBio is a biotechnology company dedicated to developing curative gene editing therapies for genetic disorders. It focuses on innovative in vivo gene editing tools and delivery systems.
Base Therapeutics
Series A in 2024
Base Therapeutics is focused on developing innovative cell and gene editing technologies to address cancerous diseases. The company has created a natural killer cell genetic engineering platform, along with various cell therapy products aimed at treating several types of cancer, including lung cancer, liver cancer, glioma, and other hematological tumors. Through its advanced technologies, Base Therapeutics aims to enhance the safety and effectiveness of clinical applications of gene editing, both in vivo and in vitro, providing healthcare professionals with improved treatment options for patients suffering from these serious conditions.
Guoke Ling Fiber
Seed Round in 2024
Guoke Ling Fiber focuses on technological research and industrialization of key materials for hydrogen fuel cells. Guoke offers carbon fiber base paper and carbon paper production lines.
Guoke Ling Fiber
Angel Round in 2023
Guoke Ling Fiber focuses on technological research and industrialization of key materials for hydrogen fuel cells. Guoke offers carbon fiber base paper and carbon paper production lines.
Immuno Cure
Series A in 2023
Immuno Cure is a biotechnology company focused on the research and development of immunotherapies targeting cancer, inflammatory diseases, and infectious disorders. The company leverages its patented technology platforms, including PD-1-enhanced DNA vaccines and Anti-42PD1 Antibody Immune Blockade, to create innovative therapeutic solutions. By concentrating on immunotherapeutic approaches, Immuno Cure aims to deliver reliable and effective treatments that address significant medical needs in oncology and beyond. Through its commitment to advancing the field of immunotherapy, the company seeks to improve patient outcomes and contribute to the evolution of modern medicine.
BioMed Technology Holdings
Seed Round in 2023
BioMed Technology Holdings specializes in personalized healthcare solutions, focusing on intestinal health. The company offers a range of advanced biomedical tests, including intestinal microbiome testing, which helps identify and address common health issues faced by urban populations. Through its comprehensive services, BioMed provides not only sophisticated testing performed by professionals but also interprets results and offers recommendations for maintaining a healthy lifestyle. This holistic approach combines traditional specialist diagnosis with innovative treatments, aiming to enhance individuals' understanding of their intestinal health and the role of probiotics in their wellbeing.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.